Drug discovery startup GTN lands £2.1m Seed from Octopus Ventures

May 4, 2018 · uktech.news

Noornew2 898x505

London-based startup GTN has raised £2.1m in Seed funding in a round led by Octopus Ventures to transform drug discovery.

Pentech and existing investor Entrepreneur First also contributed to the round, which will be used to build on GTN’s drug discovery technology.

On average, bringing a new drug to the market costs $2.9bn and takes 15 years, with a high chance of failure; plus an expected 50% drop in R&D output every nine years.

GTN, a female-led company, has developed a technology called Generative Tensorial Networks. It combines and builds upon techniques from machine learning and quantum physics to simulate, filter and discover new molecules. The company says this will help bring efficiencies to the drug development cycle, discovering much-needed medicines for patients with cancer, autoimmune and infectious diseases.

Read Complete Article

RT @HelloUpstream: We're organising our #events for 2019 and would love to hear from you on what topics you'd like us to cover? #startups…

One of my priorities is to tackle violence against women and girls in the capital. I’ve repeatedly called for legis… https://t.co/EvFUbglIx0

#TechX365: Investment is a big deal in the tech startup world, with billions getting invested into thousands of sta… https://t.co/QM4gKXw7wu

Data breaches, cyberattacks are top global risks alongside natural disasters and climate change https://t.co/tmCC8deTal by @dannyjpalmer

US soldiers have been killed by an explosion in Syria while carrying out a 'routine patrol' two weeks after Donald… https://t.co/JMabGzaQwL